Literature DB >> 25295932

The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.

Xue Chen1, Hongxing Liu2, Haizhou Xing3, Hui Sun3, Ping Zhu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25295932     DOI： 10.1038/nm.3638

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Authors:  King Pan Ng; Axel M Hillmer; Charles T H Chuah; Wen Chun Juan; Tun Kiat Ko; Audrey S M Teo; Pramila N Ariyaratne; Naoto Takahashi; Kenichi Sawada; Yao Fei; Sheila Soh; Wah Heng Lee; John W J Huang; John C Allen; Xing Yi Woo; Niranjan Nagarajan; Vikrant Kumar; Anbupalam Thalamuthu; Wan Ting Poh; Ai Leen Ang; Hae Tha Mya; Gee Fung How; Li Yi Yang; Liang Piu Koh; Balram Chowbay; Chia-Tien Chang; Veera S Nadarajan; Wee Joo Chng; Hein Than; Lay Cheng Lim; Yeow Tee Goh; Shenli Zhang; Dianne Poh; Patrick Tan; Ju-Ee Seet; Mei-Kim Ang; Noan-Minh Chau; Quan-Sing Ng; Daniel S W Tan; Manabu Soda; Kazutoshi Isobe; Markus M Nöthen; Tien Y Wong; Atif Shahab; Xiaoan Ruan; Valère Cacheux-Rataboul; Wing-Kin Sung; Eng Huat Tan; Yasushi Yatabe; Hiroyuki Mano; Ross A Soo; Tan Min Chin; Wan-Teck Lim; Yijun Ruan; S Tiong Ong
Journal:  Nat Med       Date:  2012-03-18       Impact factor: 53.440
  1 in total
  8 in total

1.  Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.

Authors:  S Tiong Ong; Charles T H Chuah; Tun Kiat Ko; Axel M Hillmer; Wan-Teck Lim
Journal:  Nat Med       Date:  2014-10       Impact factor: 53.440

Review 2.  The pharmacogenomics of drug resistance to protein kinase inhibitors.

Authors:  Nancy K Gillis; Howard L McLeod
Journal:  Drug Resist Updat       Date:  2016-07-05       Impact factor: 18.500

Review 3.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

4.  The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis.

Authors:  Qian Zou; Ping Zhan; Tangfeng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2015-12

5.  The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.

Authors:  Hou-Qun Ying; Jie Chen; Bang-Shun He; Yu-Qin Pan; Feng Wang; Qi-Wen Deng; Hui-Ling Sun; Xian Liu; Shu-Kui Wang
Journal:  Sci Rep       Date:  2015-06-15       Impact factor: 4.379

6.  The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis.

Authors:  Jinyun Xu; Jiaowei Gu; Yan Zhao; Huihua Meng; Li'an Du; Ruibo Zhang; Hao Jiang; Jianming Luo
Journal:  Oncotarget       Date:  2017-09-22

7.  Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism.

Authors:  Si-Yang Liu; Jia-Ying Zhou; Wen-Feng Li; Hao Sun; Yi-Chen Zhang; Hong-Hong Yan; Zhi-Hong Chen; Chun-Xiang Chen; Jun-Yi Ye; Jin-Ji Yang; Qing Zhou; Xu-Chao Zhang; Yi-Long Wu
Journal:  Clin Transl Med       Date:  2020-01

8.  BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer: An updated meta-analysis.

Authors:  Wenxia Su; Xiaoyun Zhang; Xin Cai; Meiyu Peng; Fengbin Wang; Yuliang Wang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.